How much funding has Dice Therapeutics raised?

Dice Therapeutics has raised $60.0M in total funding, most recently a Series B round.

Who are Dice Therapeutics's investors?

Dice Therapeutics's investors include Eli Lilly, RA Capital Management, Sands Capital, Northpond Ventures, Janus Henderson Investors, Deep Track Capital.

When was Dice Therapeutics founded?

Dice Therapeutics was founded in 2013.

Where is Dice Therapeutics headquartered?

Dice Therapeutics is headquartered in South San Francisco, California, United States.

What industry is Dice Therapeutics in?

Dice Therapeutics operates in Biotech, pharmaceuticals.

How many employees does Dice Therapeutics have?

Dice Therapeutics has 51-200 employees.

Dice Therapeutics

Acquired

South San Francisco, United States · Founded 2013 · $60.0M raised

Biotech

pharmaceuticals

Headquarters: South San Francisco, California
Employees: 51–200
Founded: 2013
Business Model: B2B

Website: dicetherapeutics.com
Total Funding: $60.0M
Last Round: $60.0M Series BAug 2021
Rounds: 2

About

DICE Therapeutics was a clinical-stage biopharmaceutical company based in South San Francisco, California, focused on discovering and developing oral small molecule therapies that target protein-protein interactions — a class of targets traditionally considered undruggable. Founded in 2013 by CEO Kevin Judice and Phil Patten, DICE developed its proprietary DC Platform to identify small molecules capable of modulating large and complex protein interfaces with high selectivity. The company was acquired by Eli Lilly in 2023.

Summary

Dice Therapeutics is a Biotech company based in South San Francisco, United States, founded in 2013. It has raised $60.0M in total across 2 rounds, most recently a $60.0M Series B round in Aug 2021. Investors include Eli Lilly, RA Capital Management and Sands Capital.